Lead: Institut national de la santé et de la recherche médicale (INSERM)

Partners: RegionH, ISCIII, NIHD

To determine whether different HIV testing strategies are (cost) effective in different settings, regions and priority groups within Europe, WP6 will estimate the survival benefits, costs and cost-effectiveness of innovative HIV testing strategies in Europe. There are to be three phases to this work package:

    1)     Multiple HIV testing strategies will be compared to current HIV testing including: indicator-condition guided testing (in hospital and General Practitioner settings); Enhanced Targeted HIV Screening; HIV testing in STD clinics, TB and hepatitis clinics; HIV testing in Voluntary Counselling and Testing (VCT) Units; Community-based HIV testing programs using rapid tests; Home self-testing; A combination of the testing strategies above in addition to the current testing strategy; Routine testing of men; Routine testing of women, men and migrants from sub-Saharan Africa, and; Routine testing of the general population. Data shall be collected on the performance of each HIV testing strategy, the proportion of undiagnosed HIV-infected patients detected and CD4 count at diagnosis, and determine the probability of linkage to HIV care upon diagnosis for each strategy (WP 4).

    2)     Cost-effectiveness analyses on the aforementioned testing strategies will be performed, based upon available data from France, Spain, the UK and Estonia.

    3)    Findings are to be extrapolated to other European countries to produce country/regional-specific guidance tools for choosing cost-effective testing strategies. This WP will also feed into and be developed in synergy with the on-going ECDC project: “Analysing cost-effectiveness for screening strategies for HIV and hepatitis B/C”

 Contact: Yazdan Yazdanpanah: yazdan.yazdanpanah@bch.aphp.fr